GlassScriptPhysician profile
Alan Bert Haratz
NPI 1336155688
$7,834.30
in general payments reported to CMS, 2019-2025
39 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $409 · 2021: $1,384 · 2022: $1,283 · 2023: $1,413 · 2024: $1,090 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,166 · Education: $59.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,165.72 |
| Education | $59.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,114.07 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $948.19 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $843.79 | 2021-2025 | Lupkynis |
| Amgen INC. | $614.32 | 2019-2025 | Tavneos, Krystexxa, Uplizna |
| Opko Pharmaceuticals, LLC | $573.78 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $386.27 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $373.38 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $318.44 | 2021-2025 | Benlysta, Jesduvroq, Shingrix |
| Fresenius USA Marketing, INC. | $256.67 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Horizon Therapeutics Plc | $238.71 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $236.60 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.10 | 2023-2025 | Jardiance |
| Ardelyx, INC. | $201.75 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Arbor Pharmaceuticals, INC. | $172.91 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $145.66 | 2020-2025 | Terlivaz, Acthar |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Haratz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.